

Table 1. Paediatric liver and kidney transplantations performed between June 2020 and May 2021 in Singapore

	Age, months/ Sex/ Weight, kg	Primary disease	PELD for liver recipient	Pre-transplant COVID-19 swab (donor and recipient) ^a		Blood products given, mL	ICU/Hospital stay, days		Immunosuppression regime		Follow-up, months	Graft survival/ Patient survival (%)	Transplant-related complications in recipient
				D-7	D-2		Donor	Recipient	Induction	Maintenance			
K1	207/M/54	Bilateral dysplastic kidneys	-	Neg	Neg	Nil	0/5	5/38	Methylpred Basiliximab ^b MMF	Prednisolone Tacrolimus MMF	15	100/100	Nil
K2	230/F/50.9	FSGS	-	Neg	Neg	Nil	0/7	5/28	Methylpred Basiliximab ^b MMF	Prednisolone Tacrolimus MMF	14	100/100	Antibody-mediated rejection (non-HLA)
K3	114/F/19.8	Congenital solitary cystic dysplastic kidney	-	Neg	Neg	Nil	0/5	5/42	Methylpred Basiliximab ^b MMF	Prednisolone Tacrolimus MMF	12	100/100	Nil
K4	63/F/14.9	Denys-Drash syndrome	-	Neg	Neg	980	0/5	8/44	Methylpred Basiliximab ^b MMF	Prednisolone Tacrolimus MMF	8	100/100	Intraoperative bleeding from graft gonadal vein/hilar fat
K5	222/M/53.2	Alport syndrome	-	Neg	Neg	Nil	0/6	5/10	Methylpred Basiliximab ^b MMF	Prednisolone Tacrolimus MMF	4	100/100	Nil
L1	33/M/11	Biliary atresia	13	Neg	Neg	255	0/6	4/26	-	Prednisolone Tacrolimus	12	100/100	Nil
L2	14/F/10.25	Biliary atresia	20.4	Neg	Neg	415	0/6	5/24	-	Prednisolone Tacrolimus	11	100/100	Pneumothorax Mild ACR
L3	16/F/9.31	Biliary atresia	25.6	Neg	Neg	1275	0/7	7/79	-	MMF Prednisolone Tacrolimus	8	100/100	PV thrombosis Abdominal abscess EBV-hepatitis

ACR: acute cellular rejection; D-2: within 48 hours prior to transplant; D-7: 7 days prior to transplant; EBV: Epstein Barr virus; FSGS: focal segmental glomerulosclerosis; ICU: intensive care unit; HLA: human leukocyte antigen; K1–5: kidney transplant numbers 1–5; L1–3: liver transplant numbers 1–3; Methylpred: methylprednisolone; MMF: mycophenolic mofetil; Neg: negative; PELD: paediatric end-stage liver disease score
^a Swab from nasopharynx and oropharynx for SARS-CoV-2-RT-PCR
^b Basiliximab was given on day 0 and day 4

Notes:
None of the donors or recipients received any COVID-19 vaccine.
Among the kidney transplant recipients, case K3 was a pre-emptive transplant.
The immunosuppression practice remained the same pre-COVID-19 and during COVID-19.